+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Central Nervous System (CNS) Stimulant Drugs Market 2019-2023 - Product Image

Global Central Nervous System (CNS) Stimulant Drugs Market 2019-2023

  • ID: 4804063
  • Report
  • Region: Global
  • 121 Pages
  • TechNavio
UP TO OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • GlaxoSmithKline Plc
  • Novartis AG
  • Pfizer Inc.
  • MORE

Global Central Nervous System (CNS) Stimulant Drugs Market: About this market

Central nervous system stimulant drugs are primarily used to treat CNS disorders. These stimulants act by increasing the dopamine level in the brain, which increases the blood pressure and heart rate. The central nervous system stimulant drugs market analysis considers sales from attention-deficit hyperactivity disorder, narcolepsy, and others. This analysis also considers the sales of central nervous system stimulant drugs in Asia, Europe, North America, and ROW. In 2018, the attention-deficit hyperactivity disorder segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the increasing prevalence of this disorder among children and adolescents, easy availability of stimulants will play a significant role in the attention-deficit hyperactivity disorder segment to maintain its market position. Also, our global central nervous system stimulant drugs market report also looks at factors such as rise in CNS disorders, approval of new stimulants, and increasing use of stimulants worldwide. However, numerous side effects of drugs, development of the first-in-class therapeutics, and increasing demand for non-pharmacological therapies may hamper the growth of the central nervous system stimulant drugs industry over the forecast period.

Global Central Nervous System (CNS) Stimulant Drugs Market: Overview

The rise in CNS disorders

CNS disorders such as sleep apnea, narcolepsy, and attention-deficit hyperactivity disorder have witnessed a significant rise in recent years. Attention-deficit hyperactivity disorder interferes with the functioning and development of a person. This increasing prevalence of CNS disorders will lead to the expansion of the global central nervous system stimulant drugs market at a CAGR of over 5% during the forecast period.

Rising demand to legalize cannabis worldwide

Cannabis can increase the dopamine level in the brain and is used widely in the treatment of attention-deficit hyperactivity disorder. According to researcher’s synthetic cannabis may have benefits on people with sleep apnea due to the modulatory effects of these drugs on serotonin-mediated apneas. This demand to legalize cannabis across the world is expected to have a positive impact on the overall market growth.

Competitive Landscape

With the presence of a few major players, the global central nervous system stimulant drugs market is concentrated. This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several central nervous system stimulant drugs manufacturers, that include GlaxoSmithKline Plc, Johnson & Johnson Services Inc., Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd.

Also, the central nervous system stimulant drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • GlaxoSmithKline Plc
  • Novartis AG
  • Pfizer Inc.
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY APPLICATION
  • Market segmentation by application
  • Comparison by application
  • Attention-deficit hyperactivity disorder - Market size and forecast
  • 2018-2023
  • Narcolepsy - Market size and forecast 2018-2023
  • Others - Market size and forecast 2018-2023
  • Market opportunity by application
PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 11: MARKET TRENDS
  • R&D of stimulants to treat attention-deficit hyperactivity disorder
  • Rising demand to legalize cannabis worldwide
  • Increasing repurposing of drugs
PART 12: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
PART 13: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • GlaxoSmithKline Plc
  • Johnson & Johnson Services Inc.
  • Novartis AG
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
PART 14: APPENDIX
  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors
List of Exhibits
Exhibit 01: Global central nervous system (CNS) disorders drugs market
Exhibit 02: Segments of global central nervous system (CNS) disorders drugs market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Product overview
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Application - Market share 2018-2023 (%)
Exhibit 19: Comparison by application
Exhibit 20: Attention-deficit hyperactivity disorder - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Attention-deficit hyperactivity disorder - Year-over-year growth 2019-2023 (%)
Exhibit 22: Narcolepsy - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Narcolepsy - Year-over-year growth 2019-2023 (%)
Exhibit 24: Others - Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Others - Year-over-year growth 2019-2023 (%)
Exhibit 26: Market opportunity by application
Exhibit 27: Customer landscape
Exhibit 28: Market share by geography 2018-2023 (%)
Exhibit 29: Geographic comparison
Exhibit 30: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: North America - Year-over-year growth 2019-2023 (%)
Exhibit 32: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 36: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 37: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 38: Key leading countries
Exhibit 39: Market opportunity
Exhibit 40: Impact of drivers and challenges
Exhibit 41: Vendor landscape
Exhibit 42: Landscape disruption
Exhibit 43: Vendors covered
Exhibit 44: Vendor classification
Exhibit 45: Market positioning of vendors
Exhibit 46: GlaxoSmithKline Plc - Vendor overview
Exhibit 47: GlaxoSmithKline Plc - Business segments
Exhibit 48: GlaxoSmithKline Plc - Organizational developments
Exhibit 49: GlaxoSmithKline Plc - Geographic focus
Exhibit 50: GlaxoSmithKline Plc - Segment focus
Exhibit 51: GlaxoSmithKline Plc - Key offerings
Exhibit 52: Johnson & Johnson Services Inc. - Vendor overview
Exhibit 53: Johnson & Johnson Services Inc. - Business segments
Exhibit 54: Johnson & Johnson Services Inc. - Organizational developments
Exhibit 55: Johnson & Johnson Services Inc. - Geographic focus
Exhibit 56: Johnson & Johnson Services Inc. - Segment focus
Exhibit 57: Johnson & Johnson Services Inc. - Key offerings
Exhibit 58: Novartis AG - Vendor overview
Exhibit 59: Novartis AG - Business segments
Exhibit 60: Novartis AG - Organizational developments
Exhibit 61: Novartis AG - Geographic focus
Exhibit 62: Novartis AG - Segment focus
Exhibit 63: Novartis AG - Key offerings
Exhibit 64: Pfizer Inc. - Vendor overview
Exhibit 65: Pfizer Inc. - Business segments
Exhibit 66: Pfizer Inc. - Organizational developments
Exhibit 67: Pfizer Inc. - Geographic focus
Exhibit 68: Pfizer Inc. - Segment focus
Exhibit 69: Pfizer Inc. - Key offerings
Exhibit 70: Teva Pharmaceutical Industries Ltd. - Vendor overview
Exhibit 71: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibit 72: Teva Pharmaceutical Industries Ltd. - Organizational developments
Exhibit 73: Teva Pharmaceutical Industries Ltd. - Segment focus
Exhibit 74: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 75: Validation techniques employed for market sizing
Exhibit 76: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • GlaxoSmithKline Plc
  • Novartis AG
  • Pfizer Inc.
  • MORE
The following companies are recognised as the key players in the global central nervous system stimulant drugs market: GlaxoSmithKline Plc, Johnson & Johnson Services Inc., Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the rising demand to legalize cannabis worldwide”

According to the report, one of the major drivers for this market is the rise in CNS disorders.

Further, the report states that one of the major factors hindering the growth of this market is the numerous side effects of drugs.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • GlaxoSmithKline Plc
  • Johnson & Johnson Services Inc.
  • Novartis AG
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown
Adroll
adroll